French assess extracorporeal photopheresis against element of controversy
This article was originally published in Clinica
The health technology assessment unit within the French Supreme Health Authority, Haute Autorité de Santé (HAS), is carrying out an assessment of extracorporeal photopheresis (ECP), a leukapheresis-based immunomodulatory therapy for the treatment of cutaneous T-cell lymphoma (CTCL). One of the outcomes of this work is expected to be the reimbursement in France, under certain conditions, of this therapy.
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.